Contact us
Contact a member of the Novartis team for more information.
This site is intended for healthcare professionals registered within Ireland. If you are a member of the public, please click here.
This portal is funded and owned by Novartis Ireland Limited and includes content approved by Novartis.
Adverse events reporting information can be found in the footer of this page.
Cosentyx is indicated for the treatment of moderate to severe plaque psoriasis (PsO) in adults, children and adolescents from the age of 6 years who are candidates for systemic therapy; active psoriatic arthritis (PsA) in adult patients (alone or in combination with methotrexate [MTX]) when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate; active ankylosing spondylitis (AS) in adults who have responded inadequately to conventional therapy; active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation as indicated by elevated C-reactive protein and/or magnetic resonance imaging evidence in adults who have responded inadequately to non-steroidal anti-inflammatory drugs; active moderate to severe hidradenitis suppurativa (HS; acne inversa) in adults with an inadequate response to conventional systemic HS therapy; active enthesitis-related arthritis (ERA) in patients 6 years and older (alone or in combination with MTX) whose disease has responded inadequately to, or who cannot tolerate, conventional therapy; active juvenile psoriatic arthritis (JPsA) in patients 6 years and older (alone or in combination with MTX) whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.1
Cosentyx is intended for use under the guidance and supervision of a physician experienced in the diagnosis and treatment of conditions for which Cosentyx is indicated.1
In Ireland Cosentyx is reimbursed for the following indications: adult plaque psoriasis (PsO); psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA).
Please refer to the Summary of Product Characteristics (SmPC) for full prescribing information and safety profile.1
Cosentyx is intended for use under the guidance and supervision of a physician experienced in the diagnosis and treatment of conditions for which Cosentyx is indicated. Please refer to the Cosentyx SmPC for full product information before prescribing.1
*‘Patients’ refers to patients that have been prescribed Cosentyx for any indication since launch.7
AS, ankylosing spondylitis; axSpA, axial spondyloarthritis; ERA, enthesitis-related arthritis; HS, hidradenitis suppurativa; JPsA, juvenile psoriatic arthritis; MTX, methotrexate; nr-axSpA, non-radiographic axial spondyloarthritis; PsA, psoriatic arthritis; PsO, plaque psoriasis; SmPC, summary of product characteristics.
References
Cosentyx® (secukinumab) Summary of Product Characteristics. Available at: www.medicines.ie.
European Medicines Agency. Cosentyx EPAR Medicines Overview. Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/cosentyx [Accessed June 2026].
Coates L, et al. RMD Open 2023;9(2):e002939.
ClinicalTrials.gov. Search results for ‘secukinumab’. Available at: https://clinicaltrials.gov/search?intr=Secukinumab&viewType=Table [Accessed June 2026].
ClinicalTrials.gov. Multiple-loading Dose Regimen Study in Patients With Chronic Plaque-type Psoriasis. Available at: https://clinicaltrials.gov/study/NCT00805480 [Accessed June 2026].
Ramonda R, et al. Arthritis Res Ther 2024;26(1);172.
Novartis. Novartis Second Quarter and Half Year 2025. Condensed Interim Financial Report – Supplementary Data. Available at: https://www.novartis.com/sites/novartiscom/files/2025-07-interim-financial-report-en.pdf [Accessed June 2026].
Novartis Data on File. Cosentyx Periodic Safety Update Report (PSUR); 26 December 2019–25 December 2020. 22 February 2021.
Sun R, et al. Dermatol Ther (Heidelb) 2024;14(3):729–743.
Novartis Data on File. Cosentyx Periodic Safety Update Report (PSUR); 26 December 2020–25 December 2023. 23 February 2023.
IE11714599 | June 2026